Антитела к Clq при системной красной волчанке биологический маркер активности, предиктор развития нефрита и неблагоприятного жизненного прогноза

1. <div><p>Ardoin S.P., Pisetsky D.S. Developments in the scientific understanding of lupus. Arthr Res Ther 2008;10:218.</p><p>Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764-6.</p><p>Mok C.C., Lau C.S. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003;56:481-90.</p><p>Sherer Y., Gorstein A., Fritzler M.J., Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthr Rheum 2004;34:501-37.</p><p>Fiegel F., Buhl A., Jaekel H.-P. et al. Autoantibodies to doublestranded DNA-Intermethod comparison between four commercial immunoassays and a research biosensor-based device. Lupus 2010;19:957.</p><p>Ho A., Magder L.S., Barr S.G., Petri M. Decreases in anti-doublestranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthr Rheum 2001;44:2342-9.</p><p>Isenberg D. Anti-dsDNA antibodies: still a useful criterion for patients with systemic lupus erythematosus? Lupus 2004;13:881-5.</p><p>Wallace D.J., Stohl W., Furie R.A. et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimum-ab in patients with active systemic lupus erythematosus. Arthr Rheum 2009;61:1168-78.</p><p>Sjowall C., Sturm M., Dahle C. et al. Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. J Rheumatol 2008;35:1994-2000.</p><p>Abbas K.A., Lichtman A.H., Pober J.S. Effector mechanisms of humoral immunity. In: Abbas K.A., Lichtman A.H., Pober J.S., eds. Cellular and molecular immunology. Philadelphia: WB Saunders, 2000:309-34.</p><p>Walport M.J. Complement. Part 1. N Engl J Med 2001;344:1058.</p><p>Ройт А., Бростофф Дж., Мейл Д. Иммунология. М., 2000.</p><p>Pickering M.C., Botto M. Are anti-C1q antibodies different from other SLE autoantibodies? Nat Rev Rheumatol 2010;6:490-3.</p><p>Botto M. Links between complement deficiency and apoptosis. Arthr Res 2001;3:207-10.</p><p>Мейл Д., Бростофф Дж., Рот Д.Б., Ройтт А. Иммунология. М.: Логосфера, 2007.</p><p>Pickering M.C., Botto M., Taylor PR. et al. Systemic lupus erythematosus, complement deficiency and apoptosis. Adv Immunol 2000;76:227-324.</p><p>Walport M.J., Morgan B.P Complement deficiency and disease. Immunol Today 1991;12:301-6.</p><p>Sellar G.C., Blake D.J., Reid K.B. Characterization and organization of the genes encoding the A-, Band C-chains of human complement subcomponent C1q. The complete derived amino acid sequence of human C1q. Biochem J 1991;274(Pt 2):481 —90.</p><p>Sim R.B., Reid K.B. C1: molecular interactions with activating systems. Immunol Today 1991;12:307-11.</p><p>Schumaker V.N., Hanson D.C., Kilchherr E. et al. A molecular mechanism for the activation of the first component of complement by immune complexes. Mol Immunol 1986;23:557-65.</p><p>Wener M.H. Autoantibodies to C1q. Seattle, WA: University of Washington, 2007;703—11.</p><p>Potlukova E., Kralikova P. Complement component C1q and anti-C1q antibodies in theory and in clinical practice. Scand J Immunol 2008;67(5):423-30.</p><p>Botto M., DelTAgnola C., Bygrave A.E. et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998;19:56-9.</p><p>Korb L.C., Ahearn J.M. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systematic lupus erythematosus revisited. J Immunol 1997;158:4525-8.</p><p>Navratil J.S., Watkins S.C., Wisnieski J.J., Ahearn J.M. The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol 2001;166:3231-9.</p><p>Gaipl U.S., Kuenkele S., Voll R.E. et al. Complement binding is an early feature of necrotic and a rather late event during apoptotic cell death. Cell Death Differ 2001;8:327-34.</p><p>Walport M.J. Complement and systemic lupus erythematosus. Arthr Res 2002;4(Suppl 3):S279-S293.</p><p>Taylor PR., Carugati A., Fadok V.A. et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 2000;192(3):359—66.</p><p>Holers V.M. Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus. J Clin Invest 2004;114:616-9.</p><p>Trendelenburg M., Marfurt J., Gerber I. et al. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthr Rheum 1999;42:187-8.</p><p>Horvath L., Czirjak L., Fekete B. et al. Levels of antibodies against C1q and 60 kDa family of heat shock proteins in the sera of patients with various autoimmune diseases. Immunol Lett 2001;75:103-9.</p><p>Seelen M.A., Trouw L.A., Daha M.R. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens 2003;12:619-24.</p><p>Trouw L.A, Roos A., Daha M.R. Autoantibodies to complement components. Mol Immunol 2001;38:199-206.</p><p>Braun A., Sis J., Max R. et al. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. Scand J Rheumatol 2007;36:291-8.</p><p>Wisnieski J.J., Jones S.M. IgG autoantibody to the collagen-like region of Clq in hypocomplementemic urticarial vasculitis syndrome, systemic lupus erythematosus, and 6 other musculoskeletal or rheumatic diseases. J Rheumatol 1992;19:884-8.</p><p>Wisnieski J.J., Jones S.M. Comparison of autoantibodies to the collagen-like region of C1q in hypocomplementemic urticarial vasculitis syndrome and systemic lupus erythematosus. J Immunol 1992;148:1396-403.</p><p>Potlukova E., Jiskra J., Limanova Z. et al. Autoantibodies against complement C1q correlate with the thyroid function in patients with autoimmune thyroid disease. Mol Immunol 2007;44:3941.</p><p>Siegert C.E., Daha M.R., Swaak A.J. et al. The relationship between serum titers of autoantibodies to C1q and age in the general population and in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1993;67:204-9.</p><p>Ravelli A., Wisnieski J.J., Ramenghi B. et al. IgG autoantibodies to complement C1q in pediatric-onset systemic lupus erythematosus. Clin Exp Rheumatol 1997;15:215-9.</p><p>Kozyro I., Perahud I., Sadallah S. et al. Clinical value of autoantibodies against C1q in children with glomerulonephritis. Pediatrics 2006;117:1663-8.</p><p>Sinico R.A., Radice A., Ikehata M. et al. Anti-C1q autoantibodies in lupus nephritis. Prevalence and clinical significance. Ann NY Acad Sci 2005;1050:193-200.</p><p>Siegert C., Daha M., Westedt L. et al. IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus. J Rheumatol 1991;18:230-4.</p><p>Edelbauer M., Kshirsagar S., Riedl M. et al. Markers of childhood lupus nephritis indicating disease activity. Pediatr Nephrol 2011;26:401-10.</p><p>Cai X.Y., Yang X.Y., Chen X.H. et al. Significance of serum anti-Clq Ab in evaluation of lupus nephritis activity and its curative effects of pharmacotherapy on lupus nephritis. Zhonghua Yi Xue Za Zhi 2004;84(17):1436-9.</p><p>Trouw L.A., Groeneveld T.W., Seelen M.A. et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004;114:679-88.</p><p>Flierman R., Daha M.R. Pathogenic role of anti-C1q autoantibodies in the development of lupus nephritis — a hypothesis. Mol Immunol 2007;44:133-8.</p><p>Smykal-Jankowiak K., Niemir Z.I., Adamczak M.P. Do circulating antibodies against C1q reflect the activity of lupus nephritis? Pol Arch Med Wewn 2011;121(9):287—95.</p><p>Akhter E., Burlingame R.W., Seaman A.L. et al. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 2011;20:1267-74.</p><p>Matrat A., Veysseyre-Balter C., Trolliet P. et al. Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus 2011;20:28-34.</p><p>Meyer O.C., Nicaise-Roland P., Cadoudal N. et al. Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthr Res Ther 2009;11:R87.</p><p>Marto N., Bertolaccini M.L., Calabuig E. et al. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005;64:444-8.</p><p>Moroni G., Radice A., Giammarresi G. et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 2009;68:234-7.</p><p>Horvath L., Czirjak L., Fekete B. et al. High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin Exp Rheumatol 2001;19:667-72.</p><p>de Moura C.G.G., Pitangueira Mangueira C.L., Sampaio Cruz L.A., Sampaio Cruz C.M. Negative anti-C1q antibody titers may influ ence therapeutic decisions and reduce the number of renal biopsies in systemic lupus erythematosus. Nephron Clin Pract 2011;118:c355-c360.</p><p>Silverman G.J. Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthr Rheum 2005;52:371-7.</p><p>Chambers S.A., Isenberg D.A. Anti-B cell therapy (Rituximab) in the treatment of autoimmune disease. Lupus 2005;14:210-4.</p><p>Vasoo S., Hughes G.R.V. Theory, targets and therapy in Systemic Lupus Erythematosus. Lupus 2005;14:181-8.</p><p>Tew W., Rabbee N., Wolslegel K. et al. Baseline autoantibody profiles predict normalization of oomplement and anti-dsDNA autoantibody levels following Rituximab treatment in systemic lupus erythematosus. Lupus 2010;19:146-57.</p><p>Looney R.J., Anolik J.H., Campbell D. et al. B cell depletion as a novel treatment for systemic lupus erythematosus. A phase I/II dose-escalation trial of rituximab. Arthr Rheum 2004;50(8):2580-9.</p><p>Lindholm C., Borjesson-Asp K., Zendjanchi K. et al. Long-term clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008;35:826-33.</p><p>Tanaka Y., Yamamoto K., Takeuchi T. et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007;17:191-7.</p><p>Anolik J.H., Barnard J., Cappione A. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthr Rheum 2004;50:3580-90.</p><p>Cornec D., Avouac J., Youinou P., Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev 2009;8(6):515-9.</p><p>Vallerskog T., Gunnarsson I., Widhe M. et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007;122:62-74.</p></div><br />